Hospira Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HOSPIRA, and when can generic versions of HOSPIRA drugs launch?
HOSPIRA has five hundred and eighteen approved drugs.
There are nine US patents protecting HOSPIRA drugs. There are seven tentative approvals on HOSPIRA drugs.
There are seventy patent family members on HOSPIRA drugs in thirty-eight countries and four hundred and twenty-two supplementary protection certificates in sixteen countries.
Summary for Hospira
| International Patents: | 70 |
| US Patents: | 9 |
| Tradenames: | 333 |
| Ingredients: | 210 |
| NDAs: | 518 |
| Patent Litigation for Hospira: | See patent lawsuits for Hospira |
| PTAB Cases with Hospira as petitioner: | See PTAB cases with Hospira as petitioner |
Drugs and US Patents for Hospira
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | M.V.I.-12 ADULT | ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin; thiamine hydrochloride; vitamin a; vitamin e | INJECTABLE;INJECTION | 008809-005 | Apr 22, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Hospira Inc | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 078815-002 | Sep 30, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-003 | Mar 13, 2013 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira | EDROPHONIUM CHLORIDE | edrophonium chloride | INJECTABLE;INJECTION | 040131-001 | Feb 24, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Hospira | NALBUPHINE HYDROCHLORIDE | nalbuphine hydrochloride | INJECTABLE;INJECTION | 070916-001 | Feb 3, 1989 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira | METOCLOPRAMIDE HYDROCHLORIDE | metoclopramide hydrochloride | INJECTABLE;INJECTION | 071990-001 | Jan 18, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hospira
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-002 | Mar 13, 2013 | 4,910,214*PED | ⤷ Sign Up |
| Hospira | TRACRIUM PRESERVATIVE FREE | atracurium besylate | INJECTABLE;INJECTION | 018831-001 | Nov 23, 1983 | 4,179,507 | ⤷ Sign Up |
| Hospira | BRETYLOL | bretylium tosylate | INJECTABLE;INJECTION | 017954-001 | Approved Prior to Jan 1, 1982 | RE29618 | ⤷ Sign Up |
| Hospira Inc | NIPENT | pentostatin | INJECTABLE;INJECTION | 020122-001 | Oct 11, 1991 | 3,923,785 | ⤷ Sign Up |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-001 | Dec 17, 1999 | 6,716,867*PED | ⤷ Sign Up |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-003 | Mar 13, 2013 | 6,716,867*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HOSPIRA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
| ➤ Subscribe | Injection | 4 mcg/mL, 50 mL and 100 mL vials | ➤ Subscribe | 2013-12-26 |
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
| ➤ Subscribe | Injection | 100 mcg/mL | ➤ Subscribe | 2009-04-08 |
| ➤ Subscribe | Injection | 4 mcg/mL, 20 mL vials | ➤ Subscribe | 2015-09-30 |
International Patents for Hospira Drugs
Supplementary Protection Certificates for Hospira Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3141251 | SPC/GB20/075 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS: POLYETHYLENE GLYCOL 3350, SODIUM SULPH; REGISTERED: IS IS/1/17/063/01 20171016; UK PL 20011/0040 20171016 |
| 2404919 | 122016000035 | Germany | ⤷ Sign Up | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, ODER EIN ESTER-PRODRUG DAVON.; REGISTRATION NO/DATE: EU/1/15/1059 20151119 |
| 2666774 | 122020000036 | Germany | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, ODER RELEBACTAM IN FORM DES MONOHYDRATES, IMIPENEM UND CILASTATIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1420 20200213 |
| 1856135 | SPC/GB20/016 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTERED: UK EU/1/19/1405 (NI) 20200113; UK PLGB 12930/0022 20200113; UK PLGB 12930/0023 20200113 |
| 2203431 | 92666 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
| 0836511 | SPC/GB06/022 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
